Vericel, a leader in advanced therapies for the sports medicine and severe burn care markets, has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus in Burlington, Mass.
The new facility, which will include approximately 125,000 sq ft of manufacturing, laboratory, and office space, will significantly increase the company’s cell therapy manufacturing capacity to support the long-term growth of its two cell therapy products: MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.
The facility is expected to be completed in 2024, with commercial manufacturing projected to begin in 2025. The campus is designed and operated in accordance with existing LEED Gold and Fitwel Level 2 certifications. The new facility will be included in those certifications.
“We expect to sustain our strong long-term revenue growth for many years given our highly innovative products, significant barriers to entry and large underpenetrated markets,” says Vericel President and Chief Executive Officer Nick Colangelo. “This important manufacturing expansion plan represents another major milestone for the company and demonstrates our confidence in the continued growth trajectory of MACI and Epicel in the years ahead. We also are very pleased to locate our new facility in a campus focused on developing and managing environmentally responsible real estate in the Boston area, which will ensure that we will have continued access to the world-class talent and infrastructure that is critical to our long-term success.”